Incorporating KOL and payer insights into the HTA process for an immunology drug

In a market with a wide patient pool and no single comparator, our client needed insights into how clinicians would use their drugs, for which patients, and in what clinical setting. This research needed to be robust beyond a typical advisory board, gaining insights that could be used in HTA submissions.

We recommended the client use the modified Delphi methodology due to its robust and recognised place in healthcare consensus. After recruiting a panel of KOLs, we facilitated a 4-stage Delphi process and wrote a validated consensus white paper.

The white paper was included in the HTA submission and published in its entirety, unredacted as part of the HTA. The position proposed by the company through the modified Delphi was accepted, and the research was recognised as a crucial part of the product achieving a positive recommendation.